Master of Pharmaceutical Science

University of Tasmania

Type of institution: University/Higher Education Institution
Level: Postgraduate
CRICOS: 00586B

The Master of Pharmaceutical Science encompasses four semesters and is considered a 2.0 year degree (i.e. semesters 1, 2, 3 and 4) to be offered at Hobart. Graduates will have gained knowledge in the pharmaceutical and pharmacological sciences, and developed skills in written and verbal communication in these areas. They will have delivered three presentations to their peers and lecturers during the completion of the course, and extensively utilised information technology. Graduates will have experienced problem solving in the pharmaceutical sciences, and will have studied the global context of pharmaceuticals. Social and ethical implications of these studies will be emphasised.

Designed for

Non-pharmacy graduates who wish to pursue a career in pharmaceuticals

Structure

6 Core Units.

Subjects

  • Pharmaceutical science

Standard entry requirements

Tertiary: A minimum of an AQF Bachelor degree in a science- based discipline from UTAS or a relevant qualification, deemed to be equivalent, from another university or tertiary institution. (Equivalence will be determined by the academic assessor, Dr Rahul Patel). Where an undergraduate degree has been recently obtained (within past 3 years), a minimum average grade of 60% obtained in the final 2 years of study would be required for entry to the Master of Pharmaceutical Science program. English Language: IELTS 6.5 (no individual band less than 6.0) International Applicants only.

Study information

CampusFeesMid year intakeAttendance
Hobart International: $67,053 No
  • Full-time : 2 years

Further information

For more information visit: http://www.utas.edu.au/courses/chm/courses/m7e-master-of-pharmaceutical-science

Related courses

Browse more courses
Is the information on this page correct? Request update
Sign up to our newsletter for the latest scholarships and education news
You must agree before submitting.

Subscribe to our newsletter

Join the conversation